9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
23 hedge funds and large institutions have $841K invested in 9 Meters Biopharma in 2020 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
600% more call options, than puts
Call options by funds: $56K | Put options by funds: $8K
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
10% more funds holding
Funds holding: 21 → 23 (+2)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
38% less capital invested
Capital invested by funds: $1.37M → $841K (-$526K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$97.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$32K |
| 3 |
ACP
Ashfield Capital Partners
San Francisco,
California
|
+$20.9K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$3.55K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.75K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$525K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$12.3K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$12K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.33K |
| 5 |
BlackRock
New York
|
-$1.84K |
NMTR Hedge Fund Activity: Q1 2020 in Review
23 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q1 2020, worth a combined $841K — down 38% from $1.37M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NMTR positions and 2 closed out — a net gain of 3 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $97.4K. The largest seller was Sabby Management, exiting entirely with an estimated $525K sold.
- 23 institutional investors held 9 Meters Biopharma (NMTR) as of Q1 2020, up from 21 in Q4 2019.
- Funds reported $841K of 9 Meters Biopharma stock for Q1 2020, down 38% quarter-over-quarter.
- 5 funds opened new 9 Meters Biopharma positions in Q1 2020 and 2 closed out, a net change of +3 holders.
- The largest 9 Meters Biopharma buyer in Q1 2020 was Renaissance Technologies, an estimated $97.4K added.
- The largest 9 Meters Biopharma seller in Q1 2020 was Sabby Management, an estimated $525K sold.
Based on aggregated 13F filings for Q1 2020.